{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:06:44Z","timestamp":1789060004378,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001592","name":"Higher Education Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117009","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:41:05Z","timestamp":1787701265000},"page":"117009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe"],"prefix":"10.1016","volume":"246","author":[{"given":"Sarah","family":"Hersey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4314-8438","authenticated-orcid":false,"given":"Haydar","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7582-3808","authenticated-orcid":false,"given":"Christopher","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Joglekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3930-8470","authenticated-orcid":false,"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2026.117009_bib1","first-page":"17","article-title":"A. Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.117009_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fepid.2023.1109853","article-title":"Patterns of care and survival for lung cancer: results of European population-based high-resolution studies","author":"Sant","year":"2023","journal-title":"Front Epidemiol"},{"key":"10.1016\/j.ejca.2026.117009_bib3","unstructured":"Accelerating Clinical Trials in the EU (ACT EU). KPI Report: January\u2013March 2025. European Medicines Agency; 2025. Accessed [May 1, 2026]. https:\/\/accelerating-clinical-trials.europa.eu\/document\/download\/a9886721-f614-4c17-a3dc-53137a63d7bc_en."},{"key":"10.1016\/j.ejca.2026.117009_bib4","unstructured":"Accelerating Clinical Trials in the EU (ACT EU). Monitoring the European Clinical Trials Environment: Quarterly Report (April\u2013June 2025). European Medicines Agency; 2025. Accessed [May 1, 2026]. https:\/\/accelerating-clinical-trials.europa.eu\/document\/download\/509efc4e-1bab-4202-86ad-444e63fb6961_en?filename=ACT+EU+Monitoring+the+European+clinical+trials+environment+Report_June_2025.docx.pdf&prefLang=fr&utm_source=chatgpt.com."},{"key":"10.1016\/j.ejca.2026.117009_bib5","unstructured":"Accelerating Clinical Trials in the EU (ACT EU). Monitoring the European Clinical Trials Environment: Quarterly Report (July\u2013September 2025). European Medicines Agency; 2025. Accessed [May 1, 2026]. https:\/\/accelerating-clinical-trials.europa.eu\/document\/download\/624dca51-f0f5-4033-9422-bc64c9e24da5_en?filename=ACT+EU+Monitoring+the+European+clinical+trials+environment+Report_September_2025.docx.pdf&prefLang=es&utm_source=chatgpt.com."},{"issue":"11","key":"10.1016\/j.ejca.2026.117009_bib6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/d41573-024-00085-5","article-title":"Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape","volume":"23","author":"Capone","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2026.117009_bib7","unstructured":"European Medicines Agency. Accelerating Clinical Trials in the EU (ACT EU): for better clinical trials that address patients' needs. Published January 13, 2022. Accessed [July 13, 2026]. https:\/\/www.ema.europa.eu\/en\/news\/accelerating-clinical-trials-eu-act-eu-better-clinical-trials-address-patients-needs."},{"key":"10.1016\/j.ejca.2026.117009_bib8","unstructured":"IQVIA Institute for Human Data Science. Global Trends in R&D 2025: Progress in Recapturing Momentum in Biopharma Innovation. IQVIA; 2025. Accessed [May 1, 2026]."},{"key":"10.1016\/j.ejca.2026.117009_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114225","article-title":"Empowering effective biomarker-driven precision oncology: a call to action","volume":"209","author":"Lawler","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117009_bib10","unstructured":"European Commission. COMBINE Project: Coordinating the Interaction of the Clinical Trials Regulation (CTR) and the In Vitro Diagnostic and Medical Devices Regulations (IVDR\/MDR)\u2014Analysis Phase Report, including Annex E (MedTech Europe Contribution). 2024. Accessed [April 4, 2026]. <underline>https:\/\/health.ec.europa.eu<\/underline>"},{"key":"10.1016\/j.ejca.2026.117009_bib11","unstructured":"MedTech Europe. Report on Administrative Burden under the In Vitro Diagnostic Medical Devices Regulation (IVDR) and Medical Devices Regulation (MDR), including Annex I. March 18, 2025. Accessed [April 4, 2026]. <underline>https:\/\/www.medtecheurope.org\/wp-content\/uploads\/2025\/03\/250318_mte-report-on-admin-burden-ivdr_mdr_final.pdf<\/underline>"},{"key":"10.1016\/j.ejca.2026.117009_bib12","unstructured":"Studna A.. The roles of central and local labs in clinical trials. Applied Clinical Trials. Published November 11, 2024. Accessed May 9, 2026. https:\/\/www.appliedclinicaltrialsonline.com\/view\/roles-central-local-labs-clinical-trials."},{"key":"10.1016\/j.ejca.2026.117009_bib13","unstructured":"Central vs local labs: laboratory and sample management. ClinicalStudies.in. Published October 7, 2025. Accessed May 9, 2026. https:\/\/www.clinicalstudies.in\/laboratory-and-sample-management\/central-vs-local-labs\/."},{"key":"10.1016\/j.ejca.2026.117009_bib14","unstructured":"Mardian Y. The shift to a centralized laboratory approach in clinical research. INA-RESPOND. Published May 31, 2023. Accessed May 9, 2026. https:\/\/ina-respond.net\/2023\/05\/31\/the-shift-to-a-centralized-laboratory-approach-in-clinical-research\/."},{"key":"10.1016\/j.ejca.2026.117009_bib15","unstructured":"Precision for Medicine. Solving the unique central lab services challenges of precision medicine trials. Published 2024. Accessed May 9, 2026. https:\/\/www.precisionformedicine.com\/blog\/solving-the-unique-central-lab-services-challenges-of-precision-medicine-trials\/."},{"key":"10.1016\/j.ejca.2026.117009_bib16","unstructured":"Central vs local lab strategies in clinical trials: how to choose, when to mix, and how to stay inspection-ready. ClinicalTrials101. Published November 16, 2025. Accessed May 9, 2026. https:\/\/www.clinicaltrials101.com\/central-vs-local-lab-strategies-in-clinical-trials-how-to-choose-when-to-mix-and-how-to-stay-inspection-ready\/."},{"key":"10.1016\/j.ejca.2026.117009_bib17","unstructured":"U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Abbott RealTime IDH2 Assay (P170005). 2017. Accessed [April 25, 2026]. <underline>https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170005B.pdf<\/underline>"},{"key":"10.1016\/j.ejca.2026.117009_bib18","unstructured":"U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Oncomine Dx Target Test (P160045). 2017. Accessed [April 11, 2026]. <underline>https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/p160045b.pdf<\/underline>"},{"key":"10.1016\/j.ejca.2026.117009_bib19","unstructured":"U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): FoundationOne\u00ae CDx. Published November 30, 2017. Accessed [Apri 11, 2026]. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019B.pdf."},{"key":"10.1016\/j.ejca.2026.117009_bib20","article-title":"Pan-tumor validation of a next-generation sequencing fraction-based microsatellite instability analysis as a companion diagnostic for pembrolizumab","volume":"8","author":"Trabucco","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117009_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100154","article-title":"High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma","volume":"36","author":"Robert","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2026.117009_bib22","article-title":"Precision medicine: what is so difficult? The interplay and complexities of pharmaceutical and diagnostic partnerships to deliver the promise of precision medicine","volume":"5","author":"Hersey","year":"2025","journal-title":"J Precis Med Health Dis"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:09:46Z","timestamp":1789056586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S0959804926007902"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117009"}}